<bill session="116" type="s" number="516" updated="2022-11-01T16:32:55Z">
  <state datetime="2019-02-14">REFERRED</state>
  <status>
    <introduced datetime="2019-02-14"/>
  </status>
  <introduced datetime="2019-02-14"/>
  <titles>
    <title type="display">Prescription Drug Monitoring Act of 2019</title>
    <title type="short" as="introduced">Prescription Drug Monitoring Act of 2019</title>
    <title type="official" as="introduced">A bill to require the use of prescription drug monitoring programs.</title>
  </titles>
  <sponsor bioguide_id="K000367"/>
  <cosponsors>
    <cosponsor bioguide_id="K000383" joined="2019-02-14"/>
    <cosponsor bioguide_id="M001183" joined="2019-02-14"/>
    <cosponsor bioguide_id="P000449" joined="2019-02-14"/>
  </cosponsors>
  <actions>
    <action datetime="2019-02-14">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2019-02-14" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="3974" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Criminal justice information and records"/>
    <term name="Drug trafficking and controlled substances"/>
    <term name="Health information and medical records"/>
    <term name="Health personnel"/>
    <term name="Intergovernmental relations"/>
    <term name="Licensing and registrations"/>
    <term name="Medical ethics"/>
    <term name="Prescription drugs"/>
    <term name="State and local government operations"/>
  </subjects>
  <amendments/>
  <summary date="2020-10-24T19:57:42Z" status="Introduced in Senate">Prescription Drug Monitoring Act of 2019 This bill expands the notification and reporting requirements with respect to potentially addictive prescription drugs for states receiving funds for a Prescription Drug Monitoring Program (PDMP). Dispensers of these drugs, which includes substances listed in schedule II, III, or IV of the Controlled Substances Act, must consult with the PDMP before starting treatment involving such drugs and report each prescription of such drugs to the PDMP within 24 hours. The state agency administering a PDMP must analyze reported data for patterns of controlled substance misuse or abuse and provide certain information to law enforcement, the public, and other states.</summary>
</bill>
